Fabry Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Online Pharmacies is the fastest growing sector, North America is the largest market

The Global Fabry Disease Treatment Market is projected to expand from USD 1.94 Billion in 2025 to USD 2.81 Billion by 2031, demonstrating a compound annual growth rate (CAGR) of 6.37%. This market focuses on delivering enzyme replacement therapies (ERT) and chaperone treatments, which are designed to counteract the alpha-galactosidase A deficiency stemming from genetic mutations. Key drivers include the broader adoption of newborn screening initiatives and supportive regulatory landscapes that promote the development of orphan drugs.

These factors contribute to earlier patient diagnosis and encourage pharmaceutical companies to invest in treatments for rare diseases; for instance, the Fabry International Network coordinated 61 member associations across 57 countries in 2025, highlighting a robust global infrastructure for diagnosis and advocacy that fuels market growth.Nevertheless, market expansion faces considerable obstacles due to the prohibitive cost of lifelong treatment, which establishes significant hurdles for reimbursement. The substantial financial strain on both healthcare systems and individual patients limits access to approved therapies, especially in areas with constrained public health budgets, thereby posing an ongoing challenge to achieving wider market penetration.

Market Drivers

A significant market driver is the robust clinical pipeline of novel therapeutics and gene therapies, which is fundamentally altering the market's direction from ongoing enzyme management towards potentially curative, one-time interventions. Pharmaceutical companies are actively developing gene editing and mRNA technologies to target the underlying genetic cause of alpha-galactosidase A deficiency, aiming to eliminate the need for lifelong, bi-weekly infusions.

This swift therapeutic progress is demonstrated by key regulatory advancements in clinical trials; for example, Sangamo Therapeutics confirmed in May 2025 that all patients in the Phase 1/2 STAAR study of their gene therapy candidate ST-920 had completed the 12-month follow-up necessary for an accelerated approval Biologics License Application, indicating that curative options are nearing commercial availability and drawing considerable investment.Concurrently, the sustained demand for Enzyme Replacement Therapies (ERT) continues to underpin the market's immediate financial performance, driven by proven efficacy and an expanding number of diagnosed patients.

As newborn screening programs enlarge the identified patient population, standard-of-care infusion therapies remain the primary source of revenue for the industry. Sanofi reported in January 2025 that sales for its core ERT, Fabrazyme, reached €269 million in Q4 2024, a 12.4% increase mainly due to better treatment adherence and new patient enrollments. While ERT holds a dominant position, the market is also strengthened by valuable alternative treatments; Amicus Therapeutics, for instance, generated $458.1 million in net product sales for its oral chaperone Galafold in full-year 2024, marking an 18% year-over-year growth that highlights the healthy and diverse economic state of the global treatment sector.

Market Challenges

The exorbitant cost associated with lifelong enzyme replacement and chaperone therapies presents a significant economic barrier, directly impeding the growth of the Global Fabry Disease Treatment Market. Despite increasing clinical demand spurred by improved diagnostics, the high per-patient expense compels healthcare payers and insurance providers to enforce stringent cost-containment strategies. These often include strict prior authorization processes, protracted coverage decisions, or outright denials of reimbursement.

Consequently, a gap emerges between a drug's regulatory approval and its actual commercial adoption, hindering pharmaceutical developers from reaching the entire eligible patient demographic and stifling revenue expansion.The consequences of this challenge are evident in the growing delays between drug approval and patient access. As reported by the European Federation of Pharmaceutical Industries and Associations in 2025, the average waiting period for patients to receive innovative medicines across Europe rose to 578 days, with only 29% of centrally approved treatments being fully accessible via public reimbursement systems. These figures underscore how financial and reimbursement obstacles effectively cap market penetration, limiting the availability of approved therapies to only a segment of eligible patients, even when effective treatments exist.

Market Trends

The introduction of second-generation, long-acting biobetter Enzyme Replacement Therapies (ERTs) is fundamentally transforming the standard of care, mitigating the substantial treatment burden linked with conventional bi-weekly infusions. In contrast to first-generation ERTs, these advanced PEGylated formulations employ chemical modifications to prolong plasma half-life and decrease immunogenicity, potentially enabling less frequent dosing and enhancing long-term patient adherence. This transition towards optimized biologics is quickly gaining market share from older treatments, as healthcare providers increasingly favor therapies that combine efficacy with greater convenience for patients.

Chiesi Farmaceutici, for example, reported in April 2025 that its Global Rare Diseases unit generated €763 million in full-year 2024 revenues, a 41% surge largely attributable to the successful commercial expansion of its long-acting therapy, Elfabrio.Concurrently, the development of novel substrate reduction therapies is diversifying the treatment landscape by introducing an oral treatment option for patients who are not suitable candidates for chaperone therapies.

These small molecules function by inhibiting glucosylceramide synthase, thereby preventing the buildup of globotriaosylceramide prior to the enzymatic defect, offering a distinct mechanism of action that could provide improved tissue penetration compared to externally administered enzymes. Pharmaceutical companies are focusing on generating robust long-term data to confirm the efficacy of this approach in stabilizing cardiac and renal function. Sanofi, in April 2025, progressed its pivotal Phase 3 CARAT study for the oral inhibitor venglustat, which is designed to run for up to 5.3 years to evaluate its sustained effectiveness in reducing left ventricular mass.

Key Market Players

• Genzyme Corporation
• Takeda Pharmaceutical Company Limited
• Amicus Therapeutics, Inc
• ISU ABXIS Co Ltd.
• JCR Pharmaceuticals Co., Ltd.
• Protalix BioTherapeutics Inc.
• Chiesi Farmaceutici S.p.A.
• Freeline Therapeutics Holdings PLC
• Yuhan Corporation
• M6P Therapeutics Inc.

Report Scope

In this report, the Global Fabry Disease Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Fabry Disease Treatment Market, by Drugs:

• Agalsidase Beta
• Migalastat
• Others

Fabry Disease Treatment Market, by Treatment:

• Enzyme Replacement Therapy (ERT)
• Chaperone Treatment
• Substrate Reduction Therapy (SRT)
• others

Fabry Disease Treatment Market, by Route of Administration:

• Oral
• Parenteral
• others

Fabry Disease Treatment Market, by Distribution Channel:

• Hospital pharmacies
• Retail pharmacies
• Online Pharmacies

Fabry Disease Treatment Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Fabry Disease Treatment Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.